Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 23c, Revenues Beat
May 6, 2021 7:51 AM EDTSyros Pharmaceuticals (NASDAQ: SYRS) reported Q1 EPS of ($0.23), $0.23 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $4.83 million versus the consensus estimate of $2.67 million.
First Quarter 2021 Financial Results
Revenues were $4.8 million for the first quarter of 2021, consisting of $4.0 million in revenue recognized under Syros collaboration with Global Blood Therapeutics, Inc. (GBT) and $0.8 million recognized under its collaboration with Incyte Corporation (Incyte). Syros recognized $2.4 million in revenue in the first quarter of 2020, including $2.2 million under its collaboration with GBT and $0.2 million under its collaboration with Incyte.Research and... More